Lapatinib (GW572016) is a potent, orally active dual tyrosine kinase inhibitor targeting both ErbB2 (HER2) and EGFR, with IC50 values of 9.8 nM and 10.2 nM, respectively. It effectively suppresses the proliferation of various cancer cell lines that overexpress EGFR or HER2, including A431 skin cancer, SK-BR-3 breast cancer, and NCI-N87 gastric cancer cells. Lapatinib induces apoptosis and significantly reduces tumor growth in xenograft models, both as a monotherapy and in combination with trastuzumab. Reagent grade, for research use only.
Usually ships within 24 hours.